Why Early-Onset Cancers Are Alarming Researchers—and What It Means for Investors June 30, 2025 - Baystreet.ca Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – The current landscape of oncology is a mixed bag of results, with optimism coming from a decrease in US cancer deaths, coupled with pessimism as global cases are expected to soar. Meanwhile, another major concern that’s bubbling up is rising rates of early-onset cases in some cancers, meaning the cancer scene is getting younger. Sadly, proposed budget cuts could slash funding for the National Cancer Institute by as much as 40%, raising alarms about future support for federally backed research. With these rising concerns happening across oncology, much of the innovation burden appears to be shifting toward the private sector, through innovative biotechs, including Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), I-Mab (NASDAQ: IMAB), NovoCure Limited (NASDAQ: NVCR), Immuneering Corporation (NASDAQ: IMRX), and ProPhase Labs, Inc. (NASDAQ: PRPH). Industry forecasters now project the global oncology drug market could top US$900 billion by 2034, driven by heightened demand for precision diagnostics and immune-based therapies. For investors, it’s a key moment to back the next wave of oncology innovation. Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) has further strengthened its executive team with the appointment of Andrew Aromando as Chief Business Officer, signaling an intensified focus on business development and strategic partnerships. Aromando brings more than 30 years of biopharma experience and—alongside recently appointed CEO Jared Kelly—previously played a central role in Ambrx Biopharma’s $2 billion acquisition by Johnson & Johnson. His arrival marks a leadership pivot aimed at unlocking value from pelareorep through late-stage development and corporate activity. “Andrew’s experience will be invaluable as we pursue aggressive clinical and business development strategies to maximize the value of pelareorep on an accelerated timeline,” said Kelly. “He is a proven industry leader with a successful track record of navigating complex transactions and partnerships and an outstanding addition to our executive team.” In his new role, Aromando will lead global business development and help shape the company’s corporate, clinical, and regulatory strategies. Among his top priorities will be optimizing the value of pelareorep’s clinical data across multiple tumor types, including pancreatic, breast, and anal cancers. “I’m thrilled to join Oncolytics at such a pivotal moment in its evolution,” said Aromando. “With promising data in difficult-to-treat cancers and a compelling body of clinical evidence in over 1,100 patients, I believe the Company is uniquely positioned to deliver meaningful value to patients and other stakeholders in the near term.” Aromando has held senior leadership roles at oncology-focused biopharmas and global service firms, with emphasis on strategic planning, portfolio optimization, and product commercialization. He holds a BA from The College of New Jersey and an MA from Rutgers University. Kelly added, “Pelareorep’s clinical data across multiple tumors is striking and represents the potential for a true backbone immunotherapy to address many in-need indications. The data show pelareorep creates a robust immune response in hard-to-treat cancers and improves survival in populations where prior therapies have failed.” Together, Kelly and Aromando are spearheading a strategy to advance pelareorep through late-stage development while maintaining capital discipline and strategic flexibility. The program continues to yield data supporting its potential across a range of aggressive cancers. Pelareorep currently holds FDA Fast Track designation for two indications—metastatic pancreatic ductal adenocarcinoma (mPDAC) and HR+/HER2- metastatic breast cancer (mBC)—underscoring regulatory interest in the program. Across clinical trials, the viral-based immunotherapy has demonstrated immune activation, synergy with checkpoint inhibitors and chemotherapy, and encouraging efficacy in heavily pretreated patients. In mPDAC, a Phase 2 cohort reported objective response rates (ORR) above 60% in tumor-evaluable patients, well above historical benchmarks. Survival outcomes at two years also exceeded expectations. In HR+/HER2- mBC, randomized Phase 2 trials (IND-213 and BRACELET-1) showed overall survival trends supporting continued development. In anal cancer, a Phase 2 cohort combining pelareorep with a checkpoint inhibitor produced partial or complete responses that surpassed historical rates for checkpoint monotherapy—further hinting at pelareorep’s broad applicability. With multiple cohorts progressing in the GOBLET study, including an externally supported pancreatic cancer arm, Oncolytics appears well-positioned to maintain clinical momentum while executing on strategic growth. Notably, prior to the appointments of Kelly and Aromando, Oncolytics presented new GOBLET data at the 2025 ASCO Annual Meeting, demonstrating pelareorep’s ability to activate both innate and adaptive immune responses in metastatic pancreatic cancer. With compelling clinical evidence and new leadership in place, Oncolytics is moving forward with renewed purpose—advancing its lead asset and aligning operations for future partnership and commercialization opportunities. CONTINUED… Read this and more news for Oncolytics Biotech at: https://usanewsgroup.com/2023/10/02/the-most-undervalued-oncolytics-company-on-the-nasdaq/ In other recent industry developments and happenings in the market include: I-Mab (NASDAQ: IMAB) recently reported positive Phase 1b data for givastomig in combination with immunochemotherapy for first-line treatment of metastatic gastric cancers. The study showed a 71% objective response rate across all dose levels, rising to 83% at the selected expansion doses, with responses observed even in tumors with low PD-L1 or CLDN18.2 expression. “Givastomig shows promising activity in the first line setting, with responses that are both rapid onset and durable, deepening over time,” said Phillip Dennis, MD, PhD, Chief Medical Officer of I-Mab. “This is the first study to evaluate givastomig in combination with immunochemotherapy and we are very pleased by the overall tolerability, consistent pharmacokinetic data and soluble 4-1BB induction.” The treatment showed a favorable safety profile, with no dose-limiting toxicities reported and no Grade 4 or 5 adverse events observed. NovoCure Limited (NASDAQ: NVCR) has announced positive results from its Phase 3 PANOVA-3 trial evaluating Tumor Treating Fields (TTFields) therapy in combination with gemcitabine and nab-paclitaxel for unresectable, locally advanced pancreatic cancer. The study met its primary endpoint, with patients receiving TTFields experiencing a statistically significant improvement in median overall survival (16.2 months vs. 14.2 months, p=0.039), as well as notable gains in pain-free and quality-of-life measures. "Most people with pancreatic cancer are diagnosed with advanced disease, which is very difficult to treat and only about 1 in 10 people are alive five years after diagnosis," said Nicolas Leupin, MD, PhD, Chief Medical Officer, Novocure. "We plan to submit these data to the FDA in the second half of 2025 to support a premarket approval for Tumor Treating Fields therapy." Immuneering Corporation (NASDAQ: IMRX) recently announced new Phase 2a data for atebimetinib (IMM-1-104) in first-line pancreatic cancer, reporting 94% overall survival and 72% progression-free survival at six months in combination with modified gemcitabine/nab-paclitaxel (mGnP). “These exceptional data demonstrate the potential of atebimetinib plus mGnP to dramatically extend the lives of patients with advanced pancreatic cancer,” said Ben Zeskind, Ph.D., Co-founder and CEO of Immuneering. “94% overall survival at 6 months is remarkable in first-line pancreatic cancer patients. Our ultimate goal is to help cancer patients outlive their disease, and today’s announcement represents an important milestone on that journey.” The trial showed a 39% overall response rate and 81% disease control rate, with no median OS or PFS reached at data cutoff. The treatment was well tolerated, showing a potentially best-in-class safety profile compared to current standards. ProPhase Labs, Inc. (NASDAQ: PRPH) recently announced strong validation data for its BE-Smart™ test, a next-generation molecular diagnostic for esophageal cancer. “The ability to run BE-Smart on brush biopsy samples opens the door to much broader clinical use,” said Ted Karkus, CEO at ProPhase Labs. “Many leading molecular diagnostics cannot be used with brush biopsies. BE-Smart now stands apart as the only advanced molecular test designed to work with both forceps biopsies and brush-based tissue collection. We are now working toward commercialization as a laboratory developed test (LDT) with a target market of roughly $10 billion dollars, representing an exciting future for our Company.” The study showed a >95% technical success rate when used with brush biopsy samples, a less invasive alternative to forceps biopsy. With a U.S. clinical launch expected in the next 2–3 quarters, BE-Smart could become a powerful early detection tool for high-risk patients with GERD, Barrett’s esophagus, and esophageal adenocarcinoma. Source: https://usanewsgroup.com/2024/09/21/is-oncolytics-biotech-the-markets-most-undervalued-cancer-opportunity/ CONTACT: Baystreet.ca [email protected] (250) 999-4849 DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Baystreet.ca is a wholly-owned subsidiary of Baystreet.ca Media Corp. (“BAY”) BAY has been not been paid a fee for Oncolytics Biotech Inc. advertising and/or digital media, but the owner(s) of BAY also own Market IQ Media Group, Inc., which has been paid a fee from the company directly. There may be 3rd parties who may have shares Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of BAY own shares of Oncolytics Biotech Inc. which were purchased in the open market. BAY and all of it’s respective employees, owners and affiliates reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by BAY has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
Why Early-Onset Cancers Are Alarming Researchers—and What It Means for Investors June 30, 2025 - Baystreet.ca Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – The current landscape of oncology is a mixed bag of results, with optimism coming from a decrease in US cancer deaths, coupled with pessimism as global cases are expected to soar. Meanwhile, another major concern that’s bubbling up is rising rates of early-onset cases in some cancers, meaning the cancer scene is getting younger. Sadly, proposed budget cuts could slash funding for the National Cancer Institute by as much as 40%, raising alarms about future support for federally backed research. With these rising concerns happening across oncology, much of the innovation burden appears to be shifting toward the private sector, through innovative biotechs, including Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), I-Mab (NASDAQ: IMAB), NovoCure Limited (NASDAQ: NVCR), Immuneering Corporation (NASDAQ: IMRX), and ProPhase Labs, Inc. (NASDAQ: PRPH). Industry forecasters now project the global oncology drug market could top US$900 billion by 2034, driven by heightened demand for precision diagnostics and immune-based therapies. For investors, it’s a key moment to back the next wave of oncology innovation. Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) has further strengthened its executive team with the appointment of Andrew Aromando as Chief Business Officer, signaling an intensified focus on business development and strategic partnerships. Aromando brings more than 30 years of biopharma experience and—alongside recently appointed CEO Jared Kelly—previously played a central role in Ambrx Biopharma’s $2 billion acquisition by Johnson & Johnson. His arrival marks a leadership pivot aimed at unlocking value from pelareorep through late-stage development and corporate activity. “Andrew’s experience will be invaluable as we pursue aggressive clinical and business development strategies to maximize the value of pelareorep on an accelerated timeline,” said Kelly. “He is a proven industry leader with a successful track record of navigating complex transactions and partnerships and an outstanding addition to our executive team.” In his new role, Aromando will lead global business development and help shape the company’s corporate, clinical, and regulatory strategies. Among his top priorities will be optimizing the value of pelareorep’s clinical data across multiple tumor types, including pancreatic, breast, and anal cancers. “I’m thrilled to join Oncolytics at such a pivotal moment in its evolution,” said Aromando. “With promising data in difficult-to-treat cancers and a compelling body of clinical evidence in over 1,100 patients, I believe the Company is uniquely positioned to deliver meaningful value to patients and other stakeholders in the near term.” Aromando has held senior leadership roles at oncology-focused biopharmas and global service firms, with emphasis on strategic planning, portfolio optimization, and product commercialization. He holds a BA from The College of New Jersey and an MA from Rutgers University. Kelly added, “Pelareorep’s clinical data across multiple tumors is striking and represents the potential for a true backbone immunotherapy to address many in-need indications. The data show pelareorep creates a robust immune response in hard-to-treat cancers and improves survival in populations where prior therapies have failed.” Together, Kelly and Aromando are spearheading a strategy to advance pelareorep through late-stage development while maintaining capital discipline and strategic flexibility. The program continues to yield data supporting its potential across a range of aggressive cancers. Pelareorep currently holds FDA Fast Track designation for two indications—metastatic pancreatic ductal adenocarcinoma (mPDAC) and HR+/HER2- metastatic breast cancer (mBC)—underscoring regulatory interest in the program. Across clinical trials, the viral-based immunotherapy has demonstrated immune activation, synergy with checkpoint inhibitors and chemotherapy, and encouraging efficacy in heavily pretreated patients. In mPDAC, a Phase 2 cohort reported objective response rates (ORR) above 60% in tumor-evaluable patients, well above historical benchmarks. Survival outcomes at two years also exceeded expectations. In HR+/HER2- mBC, randomized Phase 2 trials (IND-213 and BRACELET-1) showed overall survival trends supporting continued development. In anal cancer, a Phase 2 cohort combining pelareorep with a checkpoint inhibitor produced partial or complete responses that surpassed historical rates for checkpoint monotherapy—further hinting at pelareorep’s broad applicability. With multiple cohorts progressing in the GOBLET study, including an externally supported pancreatic cancer arm, Oncolytics appears well-positioned to maintain clinical momentum while executing on strategic growth. Notably, prior to the appointments of Kelly and Aromando, Oncolytics presented new GOBLET data at the 2025 ASCO Annual Meeting, demonstrating pelareorep’s ability to activate both innate and adaptive immune responses in metastatic pancreatic cancer. With compelling clinical evidence and new leadership in place, Oncolytics is moving forward with renewed purpose—advancing its lead asset and aligning operations for future partnership and commercialization opportunities. CONTINUED… Read this and more news for Oncolytics Biotech at: https://usanewsgroup.com/2023/10/02/the-most-undervalued-oncolytics-company-on-the-nasdaq/ In other recent industry developments and happenings in the market include: I-Mab (NASDAQ: IMAB) recently reported positive Phase 1b data for givastomig in combination with immunochemotherapy for first-line treatment of metastatic gastric cancers. The study showed a 71% objective response rate across all dose levels, rising to 83% at the selected expansion doses, with responses observed even in tumors with low PD-L1 or CLDN18.2 expression. “Givastomig shows promising activity in the first line setting, with responses that are both rapid onset and durable, deepening over time,” said Phillip Dennis, MD, PhD, Chief Medical Officer of I-Mab. “This is the first study to evaluate givastomig in combination with immunochemotherapy and we are very pleased by the overall tolerability, consistent pharmacokinetic data and soluble 4-1BB induction.” The treatment showed a favorable safety profile, with no dose-limiting toxicities reported and no Grade 4 or 5 adverse events observed. NovoCure Limited (NASDAQ: NVCR) has announced positive results from its Phase 3 PANOVA-3 trial evaluating Tumor Treating Fields (TTFields) therapy in combination with gemcitabine and nab-paclitaxel for unresectable, locally advanced pancreatic cancer. The study met its primary endpoint, with patients receiving TTFields experiencing a statistically significant improvement in median overall survival (16.2 months vs. 14.2 months, p=0.039), as well as notable gains in pain-free and quality-of-life measures. "Most people with pancreatic cancer are diagnosed with advanced disease, which is very difficult to treat and only about 1 in 10 people are alive five years after diagnosis," said Nicolas Leupin, MD, PhD, Chief Medical Officer, Novocure. "We plan to submit these data to the FDA in the second half of 2025 to support a premarket approval for Tumor Treating Fields therapy." Immuneering Corporation (NASDAQ: IMRX) recently announced new Phase 2a data for atebimetinib (IMM-1-104) in first-line pancreatic cancer, reporting 94% overall survival and 72% progression-free survival at six months in combination with modified gemcitabine/nab-paclitaxel (mGnP). “These exceptional data demonstrate the potential of atebimetinib plus mGnP to dramatically extend the lives of patients with advanced pancreatic cancer,” said Ben Zeskind, Ph.D., Co-founder and CEO of Immuneering. “94% overall survival at 6 months is remarkable in first-line pancreatic cancer patients. Our ultimate goal is to help cancer patients outlive their disease, and today’s announcement represents an important milestone on that journey.” The trial showed a 39% overall response rate and 81% disease control rate, with no median OS or PFS reached at data cutoff. The treatment was well tolerated, showing a potentially best-in-class safety profile compared to current standards. ProPhase Labs, Inc. (NASDAQ: PRPH) recently announced strong validation data for its BE-Smart™ test, a next-generation molecular diagnostic for esophageal cancer. “The ability to run BE-Smart on brush biopsy samples opens the door to much broader clinical use,” said Ted Karkus, CEO at ProPhase Labs. “Many leading molecular diagnostics cannot be used with brush biopsies. BE-Smart now stands apart as the only advanced molecular test designed to work with both forceps biopsies and brush-based tissue collection. We are now working toward commercialization as a laboratory developed test (LDT) with a target market of roughly $10 billion dollars, representing an exciting future for our Company.” The study showed a >95% technical success rate when used with brush biopsy samples, a less invasive alternative to forceps biopsy. With a U.S. clinical launch expected in the next 2–3 quarters, BE-Smart could become a powerful early detection tool for high-risk patients with GERD, Barrett’s esophagus, and esophageal adenocarcinoma. Source: https://usanewsgroup.com/2024/09/21/is-oncolytics-biotech-the-markets-most-undervalued-cancer-opportunity/ CONTACT: Baystreet.ca [email protected] (250) 999-4849 DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Baystreet.ca is a wholly-owned subsidiary of Baystreet.ca Media Corp. (“BAY”) BAY has been not been paid a fee for Oncolytics Biotech Inc. advertising and/or digital media, but the owner(s) of BAY also own Market IQ Media Group, Inc., which has been paid a fee from the company directly. There may be 3rd parties who may have shares Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of BAY own shares of Oncolytics Biotech Inc. which were purchased in the open market. BAY and all of it’s respective employees, owners and affiliates reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by BAY has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.